US FDA approves first clinical trial using embryonic stem cells

Cha Bio & Diostech, a local biopharmaceutical company, said on November 24 that the US based Advanced Cell Technology, Inc. (ACT), Cha’s joint research collaborator, received from the US Food and Drug Administration an approval on its Investigational New Drug (IND) application to immediately initiate a Phase I/II multicenter clinical trial using retinal cells derived from human embryonic stem c...